arrow
M

Mariusz Bidziński

maria sklodowska-curie national research institute of oncology
H指数:30
被引数:6,279

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer

Durvalumab联合卡铂/紫杉醇和贝伐单抗,然后durvalumab和贝伐单抗联合或不联合奥拉帕尼维持治疗新诊断的非BRCA突变晚期卵巢癌

2025-12-090
PRE
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: 1-Year Follow-Up After Final Analysis of the ENGOT-en9/LEAP-001 Phase 3 Trial

一线仑伐替尼联合帕博利珠单抗与化疗治疗晚期子宫内膜癌:ENGOT-en9/LEAP-001 III期试验最终分析后的1年随访

2025-11-110
PRE
Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v)

子宫内膜癌诊断与治疗指南更新:波兰妇科肿瘤学会(2025v)

2025-08-230
PRE
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study

VB10.16治疗性DNA疫苗与atezolizumab联合用于持续性、复发性或转移性HPV16阳性宫颈癌的安全性和有效性:一项多中心、单臂2a期研究

2025-01-071
OA
A randomized, phase 2 study of pembrolizumab plus chemotherapy with or without anti-immunoglobulin-like transcript 4 monoclonal antibody MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer
2023-04-140
PRE
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

TERT位点的多个独立变异与端粒长度以及乳腺癌和卵巢癌的风险相关

2013-03-27481
OA